EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cells

Oncology Letters

Volumn 8, Issue 1, 2014, Pages 41-46

  Chen, Peijie ^a   Huang, Yan ^a   Zhang, Bo ^a   Wang, Qiuquan ^a   Bai, Peiming ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Cell proliferation; EphA2; LNCaP cell; Prostate cancer; Tumor invasion

Indexed keywords

EPHRIN RECEPTOR A2; MATRIGEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CELL COUNTING; CELL CYCLE PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RECOMBINANT PLASMID; TUMOR INVASION; WESTERN BLOTTING;

EID: 84901243260     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2093     Document Type: Article

References (26)

1. Lindberg RA and Hunter T: cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol 10: 6316-6324, 1990.
2. Sulman EP, Tang XX, Allen C, et al: ECK, a human EPH-related gene, maps to 1p36. l, a common region of alteration in human cancers. Genomics 40: 371-374, 1997.
3. Cheng N, Brantley DM and Chen J: The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 13: 75-85, 2002.
4. Kamat AA, Coffey D, Merritt WM, et al: EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 115: 2684-2692, 2009.
5. Liu F, Park PJ, Lai W, et al: A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res 66: 10815-10823, 2006.
6. Lu M, Miller KD, Gokmen-Polar Y, et al: EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res 63: 3425-3429, 2003.
7. Walker-Daniels J, Coffman K, Azimi M, et al: Overexpression of the EphA2 tyrosinase kinase in prostate cancer. Prostate 41: 275-280, 1999.
8. Landen CN Jr, Chavez-Reyes A, Bucana C, et al: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65: 6910-6918, 2005.
9. Abraham S, Knapp DW, Cheng L, et al: Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12: 353-360, 2006.
10. Herrem CJ, Tatsumi T, Olson KS, et al: Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 11: 226-231, 2005.
11. Lin YG, Han LY, Kamat AA, et al: EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109: 332-340, 2007.
12. Brantley-Sieders DM, Zhuang G, Hicks D, et al: The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118: 64-78, 2008.
13. Taddei ML, Parri M, Angelucci A, et al: EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells. Mol Cancer Res 9: 149-160, 2011.
14. Kinch MS, Clark GJ, Der CJ and Burridge K: Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. J Cell Biol 130: 461-471, 1995.
15. Prout GR Jr: Proceedings: Diagnosis and staging of prostatic carcinoma. Cancer 32: 1096-1103, 1973.
16. Zeng G, Hu Z, Kinch MS, et al: High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 163: 2271-2276, 2003.
17. Kamat AA, Fletcher M, Gruman LM, et al: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 2: 1707-1714, 2006.
18. Margaryan NV, Strizzi L, Abbott DE, et al: EphA2 as a promoter of melanoma tumorigenity. Cancer Biol Ther 8: 279-288, 2009.
19. Parri M, Taddei ML, Bianchini F, et al: EphA2 reexpression prompts invasion of melanoma cells shifting from mesenehymal to amoeboid-like motility style. Cancer Res 69: 2072-2081, 2009.
20. Lu C, Shahzad MM, Wang H, et al: EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 7: 1098-2103, 2008.
21. Taddei ML, Parri M, Angelucci A, et al: Kinase-dependent and-independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am J Pathol 174: 1492-1503, 2009.
22. Petty A, Myshkin E, Qin H, et al: A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One 7: e42120, 2012.
23. Van den Broeck A, Vankelecom H, Van Eijsden R, et al: Molecular markers associated with outcome and metastasis in human pancreatic cancer. J Exp Clin Cancer Res 31: 68, 2012.
24. Coffman KT, Hu M, Carles-Kinch K, et al: Differential EphA2 epitope display on normal versus malignant cells. Cancer Res 63: 7907-7912, 2003.
25. Liu DP, Wang Y, Koeffler HP and Xie D: Ephrin-A1 is a negative regulator in glioma through downregulation of EphA2 and FAK. Int J Oncol 30: 865-871, 2007.
26. Mohammed KA, Wang X, Goldberg EP, et al: Silencing receptor EphA2 induces apoptosis and attenuates tumor growth in malignant mesothelioma. Am J Cancer Res 1: 419-431, 2011.